Associate Professor,Nuclear Medicine and Radiobiology, University de Sherbrooke Canada
Dr. Leyton is a leading scientist in the field of antibody-based medicines. His projects range from an effort to map new intracellular transport routes that increase the cellular accumulation of delivered therapeutic payloads for biopharmaceuticals to his most recent efforts to redefine molecular imaging for cancer so doctors can make more informed decisions for patient management and therapeutic action. Dr. Leyton earned his PhD in Molecular and Medical Pharmacology from the University of California, Los Angeles and trained as a postdoctoral fellow in the department of pharmaceutical sciences at the University of Toronto prior to joining the Universit? de Sherbrooke.